MedTechIQ_3Helix InSight Engine-Beta
Preview
Open in TheBrain
Triple Helix Discovery Engine
Triple Helix Framework
Industry
Architects: Small & Medium Size Business (SMBs), Product Development, De-Risking, Validation, Building Niche & Emerging Markets
*Architects: Biotechnology_Personalized, Precision, Preemptive Medicines
Neumora Therapeutics, Inc. (NMRA)*
Finance & Acquisitions: Neumora Therapeutics
Parents
Neumora Therapeutics, Inc. (NMRA)*
Children
2021: Investors: Arch Venture Partners, Alexandria Venture Investments, Altitude Life Science Ventures, Amgen, Catalio Capital Management, F-Prime Capital, Invus, Logos Capital, Mubadala Capital, Newpath Partners, Polaris Partners, re.Mind Capital, Softbank Vision Fund 2, Surveyor Capital, Waycross Ventures and other undisclosed investors
2022: After splashy $500M unveiling, Neumora returns with sophomore financing to fund neuroscience R&D
2022: Arch Venture Partners led the series A, which included a $100 million investment from Amgen. Both Arch and Amgen have returned for the series B, joining with fellow existing investors including F-Prime Capital and Invus and new backers such as Abu Dhabi Growth Fund to funnel $112 million into Neumora.
2022: Neumora is putting together a crossover round — the last private fundraising before an IPO — and could go public before the end of the year.
Jumps
Key People: Neumora Therapeutics
Organization & Developments: Neumora Therapeutics